About This Study
This research is being done to understand the changes in brain chemistry associated with depression in late life and with the response to antidepressant medication.
Study participants will visit the Johns Hopkins Medical Institution for an initial screening, brain scans, and mood and mental function tests. Participants experiencing depression will receive treatment with a drug called Vortioxetine (also known as Trintellix), and treatment will be monitored on a weekly basis by the study psychiatrist.
Vortioxetine (Trintellix) is an antidepressant associated with improvement in mood and cognition, particularly in patients who do not respond to SSRIs.
Further research on how depression impacts the brain and join our compensated study today!
IRB Protocol No: IRB00269869 [May 11, 2023]
Principal Investigator: Gwenn S. Smith, PhD